Show simple item record

dc.contributor.authorJames, NDen_US
dc.contributor.authorde Bono, JSen_US
dc.contributor.authorSpears, MRen_US
dc.contributor.authorClarke, NWen_US
dc.contributor.authorMason, MDen_US
dc.contributor.authorDearnaley, DPen_US
dc.contributor.authorRitchie, AWSen_US
dc.contributor.authorAmos, CLen_US
dc.contributor.authorGilson, Cen_US
dc.contributor.authorJones, RJen_US
dc.contributor.authorMatheson, Den_US
dc.contributor.authorMillman, Ren_US
dc.contributor.authorAttard, Gen_US
dc.contributor.authorChowdhury, Sen_US
dc.contributor.authorCross, WRen_US
dc.contributor.authorGillessen, Sen_US
dc.contributor.authorParker, CCen_US
dc.contributor.authorRussell, JMen_US
dc.contributor.authorBerthold, DRen_US
dc.contributor.authorBrawley, Cen_US
dc.contributor.authorAdab, Fen_US
dc.contributor.authorAung, Sen_US
dc.contributor.authorBirtle, AJen_US
dc.contributor.authorBowen, Jen_US
dc.contributor.authorBrock, Sen_US
dc.contributor.authorChakraborti, Pen_US
dc.contributor.authorFerguson, Cen_US
dc.contributor.authorGale, Jen_US
dc.contributor.authorGray, Een_US
dc.contributor.authorHingorani, Men_US
dc.contributor.authorHoskin, PJen_US
dc.contributor.authorLester, JFen_US
dc.contributor.authorMalik, ZIen_US
dc.contributor.authorMcKinna, Fen_US
dc.contributor.authorMcPhail, Nen_US
dc.contributor.authorMoney-Kyrle, Jen_US
dc.contributor.authorO'Sullivan, Jen_US
dc.contributor.authorParikh, Oen_US
dc.contributor.authorProtheroe, Aen_US
dc.contributor.authorRobinson, Aen_US
dc.contributor.authorSrihari, NNen_US
dc.contributor.authorThomas, Cen_US
dc.contributor.authorWagstaff, Jen_US
dc.contributor.authorWylie, Jen_US
dc.contributor.authorZarkar, Aen_US
dc.contributor.authorParmar, MKBen_US
dc.contributor.authorSydes, MRen_US
dc.contributor.authorSTAMPEDE Investigatorsen_US
dc.coverage.spatialUnited Statesen_US
dc.date.accessioned2017-07-19T11:29:41Z
dc.date.issued2017-07-27en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/28578639en_US
dc.identifier.citationN Engl J Med, 2017, 377 (4), pp. 338 - 351en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/707
dc.identifier.eissn1533-4406en_US
dc.identifier.doi10.1056/NEJMoa1702900en_US
dc.description.abstractBACKGROUND: Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a multigroup, multistage trial design. METHODS: We randomly assigned patients in a 1:1 ratio to receive ADT alone or ADT plus abiraterone acetate (1000 mg daily) and prednisolone (5 mg daily) (combination therapy). Local radiotherapy was mandated for patients with node-negative, nonmetastatic disease and encouraged for those with positive nodes. For patients with nonmetastatic disease with no radiotherapy planned and for patients with metastatic disease, treatment continued until radiologic, clinical, or prostate-specific antigen (PSA) progression; otherwise, treatment was to continue for 2 years or until any type of progression, whichever came first. The primary outcome measure was overall survival. The intermediate primary outcome was failure-free survival (treatment failure was defined as radiologic, clinical, or PSA progression or death from prostate cancer). RESULTS: A total of 1917 patients underwent randomization from November 2011 through January 2014. The median age was 67 years, and the median PSA level was 53 ng per milliliter. A total of 52% of the patients had metastatic disease, 20% had node-positive or node-indeterminate nonmetastatic disease, and 28% had node-negative, nonmetastatic disease; 95% had newly diagnosed disease. The median follow-up was 40 months. There were 184 deaths in the combination group as compared with 262 in the ADT-alone group (hazard ratio, 0.63; 95% confidence interval [CI], 0.52 to 0.76; P<0.001); the hazard ratio was 0.75 in patients with nonmetastatic disease and 0.61 in those with metastatic disease. There were 248 treatment-failure events in the combination group as compared with 535 in the ADT-alone group (hazard ratio, 0.29; 95% CI, 0.25 to 0.34; P<0.001); the hazard ratio was 0.21 in patients with nonmetastatic disease and 0.31 in those with metastatic disease. Grade 3 to 5 adverse events occurred in 47% of the patients in the combination group (with nine grade 5 events) and in 33% of the patients in the ADT-alone group (with three grade 5 events). CONCLUSIONS: Among men with locally advanced or metastatic prostate cancer, ADT plus abiraterone and prednisolone was associated with significantly higher rates of overall and failure-free survival than ADT alone. (Funded by Cancer Research U.K. and others; STAMPEDE ClinicalTrials.gov number, NCT00268476 , and Current Controlled Trials number, ISRCTN78818544 .).en_US
dc.format.extent338 - 351en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectAbiraterone Acetateen_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAged, 80 and overen_US
dc.subjectAndrogen Antagonistsen_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectHumansen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectNeoplasm Metastasisen_US
dc.subjectNeoplasm Recurrence, Localen_US
dc.subjectPrednisoloneen_US
dc.subjectProstate-Specific Antigenen_US
dc.subjectProstatic Neoplasmsen_US
dc.subjectSteroid 17-alpha-Hydroxylaseen_US
dc.subjectSurvival Analysisen_US
dc.titleAbiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-07-27en_US
rioxxterms.versionofrecord10.1056/NEJMoa1702900en_US
rioxxterms.licenseref.startdate2017-07-27en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfN Engl J Meden_US
pubs.issue4en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Dearnaley)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume377en_US
pubs.embargo.termsNot knownen_US
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
icr.researchteamTreatment Resistanceen_US
icr.researchteamClinical Academic Radiotherapy (Dearnaley)en_US
dc.contributor.icrauthorDearnaley, Daviden_US
dc.contributor.icrauthorAttard, Gerhardten_US
dc.contributor.icrauthorDe Bono, Johannen_US
dc.contributor.icrauthorParker, Chrisen_US
dc.contributor.icrauthorYarnold, Johnen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record